MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 20.00M | 0.00 | |
| Operating Expenses | -- | 36.47M | 32.97M | 38.06M | 46.55M | 48.03M | |
| R&D | -- | 28.11M | 25.19M | 27.57M | 34.15M | 34.94M | |
| SG&A | -- | 8.37M | 7.78M | 10.49M | 12.40M | 13.10M | |
| Operating Income | -- | -36.47M | -32.97M | -38.06M | -26.55M | -48.03M | |
| EBITDA | -- | -33.03M | -32.39M | -37.56M | -22.90M | -43.41M | |
| Pretax Income | -- | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M | |
| Income Tax | -- | 0.00 | 0.00 | 0.00 | -- | -- | |
| Net Income | -- | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M | |
| EPS Diluted | -- | -0.77 | -0.66 | -0.65 | -0.45 | -0.76 | |
| Diluted Shares | -- | 43.80M | 45.78M | 53.40M | 53.90M | 59.00M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%